LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.Ann Hematol | PMID 40397196PMC12141138 | 2025-May | 0.90 | This is an original result report from a randomized Phase III trial in oncology with a drug intervention, but it analyzes health-related quality of life as the primary/key secondary endpoint, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it is excluded. | 已完成 |
| Impact of High-Titer Convalescent Plasma on Clinical and Virologic Outcomes Among Veterans Hospitalized With SARS-CoV-2 Infection: VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1).J Med Virol | PMID 40400480无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).JCO Glob Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40403198无 PMCID | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.Ann Hematol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:生活质量量表图;Fig. 2:生活质量量表图;Fig. 3:生活质量量表图;Fig. 4:生活质量量表图;Fig. 5:生活质量量表图。 | PMID 40407887PMC12141397 | 2025-May | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Cost-utility analysis of the DREAMS START intervention for people living with dementia and their carers: a within-trial economic evaluation.Lancet Healthy Longev | PMID 40412418无 PMCID | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial.ESMO Open | PMID 40441802PMC12167881 | 2025-May | 0.45 | The abstract reports a randomized phase III trial with a drug intervention, but the primary/key secondary efficacy endpoint is patient-reported outcomes (quality of life), not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The report is therefore excluded as a quality-of-life analysis. | 待处理 |
| Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies.Eur Respir J | PMID 39884760PMC12056246 | 2025-May | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.Clin Infect Dis | PMID 39523547PMC12043053 | 2025-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study.Clin Infect Dis | PMID 39722560PMC12043065 | 2025-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.Vaccine | PMID 40179522无 PMCID | 2025-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Adjunctive Cariprazine on Anxiety Symptoms in Patients With Major Depressive Disorder: Post Hoc Analysis of a Randomized Placebo-Controlled Trial.J Clin Psychiatry | PMID 40315101无 PMCID | 2025-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4.Eur J Endocrinol | PMID 40400262无 PMCID | 2025-Apr-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study.Br J Dermatol | PMID 39607831无 PMCID | 2025-Apr-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The safety and efficacy of a single dose of oral azithromycin given in labour to prevent skin and soft tissue infections in young infants in Fiji: a randomised controlled trial.BMC Med | PMID 40289086PMC12036277 | 2025-Apr-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.N Engl J Med | PMID 40267423无 PMCID | 2025-Apr-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza.N Engl J Med | PMID 40267424无 PMCID | 2025-Apr-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trial.Sci Rep | PMID 40274842PMC12022249 | 2025-Apr-24 | 0.95 | The record describes a biomarker outcome analysis within a Phase III randomized trial (DisCoVeRy trial) for COVID-19. While it is human, randomized, Phase III, and reports time-to-event outcomes (time to hospital discharge) with HR, it is not an oncology study (COVID-19, not a malignant neoplasm). Furthermore, the primary focus is on the prognostic value of a biomarker (sST2), not on the efficacy of a drug intervention, and the report is a secondary analysis of the trial's data. Therefore, it does not meet the core eligibility criteria for an oncology drug efficacy report. | 待处理 |
| Effect of Continuous Intraoperative Dexmedetomidine on Interleukin-6 and Other Inflammatory Markers After Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial.Medicina (Kaunas) | PMID 40428745PMC12113577 | 2025-Apr-24 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improvements Over Time with Valbenazine in Elderly Adults (≥65 Years) with Tardive Dyskinesia: Post Hoc Analyses of 2 Long-Term Studies.J Clin Psychiatry | PMID 40265997无 PMCID | 2025-Apr-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Phase Ⅲ, multicenter, randomized comparative study of LY01005 and Zoladex® for patients with premenopausal breast cancer].Zhonghua Zhong Liu Za Zhi | PMID 40268551无 PMCID | 2025-Apr-23 | 0.95 | The study is a Phase III randomized trial of a drug intervention in oncology patients with primary results. However, it is not eligible because the primary efficacy endpoint is not a time-to-event outcome (OS, PFS, DFS, etc.). The primary endpoint is a pharmacodynamic measure (cumulative probability of maintaining menopausal hormone suppression level), and other endpoints are hormone changes, PK, and safety. No time-to-event analysis (e.g., Kaplan-Meier, HR for survival) is reported. | 待处理 |
| Visualizing a marker's degrees of necessity and of sufficiency in the predictiveness curve.BMC Med Res Methodol | PMID 40269760PMC12016328 | 2025-Apr-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early administration of vitamin C in patients with sepsis or septic shock in emergency departments: a multicenter, double-blind, randomized controlled trial: the C-EASIE trial.Crit Care | PMID 40269974PMC12020157 | 2025-Apr-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.RMD Open | PMID 40274305PMC12020763 | 2025-Apr-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.Blood Adv | PMID 39774762PMC12008622 | 2025-Apr-22 | 0.80 | The report describes results from Phase III randomized trials of iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), which is classified as a hematologic malignancy. However, the primary/key secondary endpoints evaluated are patient-reported outcomes (fatigue and quality of life via FACIT-Fatigue and EORTC QLQ-C30) and their correlation with hematologic markers (LDH, Hb). It does not report on a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, nor does it include Kaplan-Meier estimates or hazard ratios for such an endpoint. Therefore, it fails the time_to_event criterion and is excluded from the cohort. | 待处理 |
| Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study.Blood Adv | PMID 39853273PMC12008693 | 2025-Apr-22 | 0.85 | The record describes a Phase III randomized trial (ALPINE) in oncology with human subjects and a drug intervention. However, the abstract reports on the acquisition of resistance mutations in patients who progressed, not on the primary or key secondary time-to-event efficacy analysis (e.g., PFS, OS) of the trial. Therefore, it lacks the required time-to-event efficacy endpoint for inclusion in the Kaplan-Meier digitization cohort. | 待处理 |
| High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial.JAMA | PMID 40063041PMC11894546 | 2025-Apr-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.J Clin Oncol | PMID 39668137PMC12005862 | 2025-Apr-20 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.J Clin Oncol | PMID 39778121PMC12005868 | 2025-Apr-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine.Vaccine | PMID 40081152无 PMCID | 2025-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.Lancet | PMID 40158524无 PMCID | 2025-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.Lancet | PMID 40158526无 PMCID | 2025-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.Vaccine | PMID 40188565无 PMCID | 2025-Apr-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial.Blood疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图。 | PMID 39808798PMC12060157 | 2025-Apr-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.N Engl J Med | PMID 39927615无 PMCID | 2025-Apr-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of treating Helicobacter pylori infection on seizure frequency in children with drug-resistant idiopathic generalized epilepsy: a randomized controlled trial.Ital J Pediatr | PMID 40247384PMC12004564 | 2025-Apr-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of lenalidomide consolidation on health-related quality of life in chronic lymphocytic leukemia: ancillary study of the phase III CLL6-RESIDUUM trial.BMC Cancer | PMID 40240989PMC12004742 | 2025-Apr-16 | 0.85 | The record is an ancillary study from a Phase III trial, but its sole focus is on health-related quality of life, a secondary/safety endpoint, and does not report a primary or key secondary time-to-event efficacy endpoint like OS, PFS, or HR for such endpoints. | 待处理 |
| First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 39992668PMC11851304 | 2025-Apr-15 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 无 KM 图 |
| Four cycles of docetaxel plus cisplatin as neoadjuvant chemotherapy followed by concurrent chemoradiotherapy in stage N2-3 nasopharyngeal carcinoma: phase 3 multicentre randomised controlled trial.BMJ疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:非 KM 图。 | PMID 40233976PMC11997745 | 2025-Apr-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with De Novo Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial.Clin Cancer Res疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40008901无 PMCID | 2025-Apr-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial.Signal Transduct Target Ther | PMID 40222976PMC11994814 | 2025-Apr-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The effect of doxepin 3 mg on sleep latency: a pooled analysis of two phase 3 trials.Sleep Breath | PMID 40229607PMC11996978 | 2025-Apr-14 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.J Neurol | PMID 40220155无 PMCID | 2025-Apr-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Tadalafil on cardiac function and left ventricular dimensions in Duchenne muscular dystrophy: safety and cardiac MRI substudy results from a randomized, placebo-controlled trial.BMC Cardiovasc Disord | PMID 40217158PMC11987275 | 2025-Apr-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.Inflamm Bowel Dis | PMID 38899786PMC11985396 | 2025-Apr-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Similar Efficacy of Mesalazine in Adult and Older Adult Ulcerative Colitis Patients: Post Hoc Analysis of a Randomized Noninferiority Trial of 1600 mg vs 400 mg Tablets.Inflamm Bowel Dis | PMID 38902993PMC11985383 | 2025-Apr-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis.Inflamm Bowel Dis | PMID 39018016PMC11985380 | 2025-Apr-10 | 0.95 | The record is a secondary safety analysis from randomized controlled Phase III trials of ozanimod for ulcerative colitis and multiple sclerosis. It is not an oncology study and does not report the required survival or time-to-event efficacy outcomes for Kaplan-Meier digitization. | 待处理 |
| Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study.Inflamm Bowel Dis | PMID 39656830PMC11985404 | 2025-Apr-10 | 0.80 | The study is a randomized controlled Phase 2b/3 trial (SELECTION study) involving human participants, but the disease is ulcerative colitis, which is not oncology. Therefore, it does not meet the oncology eligibility criteria. | 待处理 |
| Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.J Clin Oncol | PMID 39746176PMC11974638 | 2025-Apr-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.J Clin Oncol | PMID 39787453PMC11974627 | 2025-Apr-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion.N Engl J Med | PMID 39908448无 PMCID | 2025-Apr-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |